EBITDA Margin % is calculated as EBITDA divided by its Revenue. Mind Medicine's EBITDA for the
three
months ended in Dec. 2024 was $-34.09 Mil. Mind Medicine's Revenue for the
three
months ended in Dec. 2024 was $0.00 Mil. Therefore, Mind Medicine's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.
Mind Medicine EBITDA Margin % Historical Data
The historical data trend for Mind Medicine's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mind Medicine's EBITDA Margin %
For the Biotechnology subindustry, Mind Medicine's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mind Medicine's EBITDA Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mind Medicine's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Mind Medicine's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mind Medicine (NAS:MNMD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Mind Medicine EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of Mind Medicine's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MNMD has been successfully added to your 